Stocks · Health care · Biological Products, (No Diagnostic Substances)

EXELIXIS, INC.

EXEL Clue Score84
United States Fiscal year ends January CIK 0000939767 Results filed 29 Oct 2026

What the insiders did Net selling

Insider
Date
Role
Action
Shares
Price
Amount
Maria C Freire
7 May 2026
Director
Sold after exercise
20,634
$46.00
$949.16K
Mary C Beckerle
7 May 2026
Director
Sold after exercise
7,712
$48.45
$373.65K
Julie Smith
18 Feb 2026
Director
Sold after exercise
20,030
$44.30
$887.33K
Julie Smith
18 Feb 2026
Director
Sold after exercise
44,087
$44.50
$1.96M
Jack L Wyszomierski
18 Feb 2026
Director
Sold after exercise
99,574
$44.01
$4.38M
Julie Smith
17 Feb 2026
Director
Sold after exercise
42,422
$43.33
$1.84M
Bob Oliver
13 Feb 2026
Director
Sold after exercise
21,162
$43.90
$929.01K
Bob Oliver
13 Feb 2026
Director
Sold after exercise
9,088
$43.61
$396.33K
Mary C Beckerle
11 Nov 2025
Director
Sold after exercise
18,838
$41.90
$789.31K
Mary C Beckerle
11 Nov 2025
Director
Sold after exercise
5,784
$42.03
$243.10K
Amy C. Peterson
16 May 2025
EVP Prod Dev & Med Aff & CMO
Sold after exercise
72,776
$45.47
$3.31M
Christopher J. Senner
16 May 2025
EVP and CFO
Sold after exercise
100,000
$46.00
$4.60M
George Poste
16 May 2025
Director
Sold after exercise
20,634
$45.99
$948.96K
Patrick J. Haley
15 May 2025
EVP, Commercial
Sold after exercise
116,383
$48.05
$5.59M
Patrick J. Haley
15 May 2025
EVP, Commercial
Sold after exercise
10,000
$46.95
$469.50K
Stelios Papadopoulos
15 May 2025
Director
Sold after exercise
15,874
$44.35
$704.01K
Stelios Papadopoulos
15 May 2025
Director
Sold after exercise
20,634
$44.35
$915.12K
Jack L Wyszomierski
28 Feb 2025
Director
Sold after exercise
8,768
$37.80
$331.43K
Julie Smith
28 Feb 2025
Director
Sold after exercise
19,294
$37.62
$725.84K
Julie Smith
27 Feb 2025
Director
Sold after exercise
54,514
$38.13
$2.08M
Bob Oliver
25 Feb 2025
Director
Sold after exercise
18,647
$37.25
$694.60K
Christopher J. Senner
24 Feb 2025
EVP and CFO
Sold after exercise
29,314
$36.14
$1.06M
Sue Gail Eckhardt
14 Feb 2025
Director
Sold after exercise
3,856
$35.04
$135.11K
Sue Gail Eckhardt
14 Feb 2025
Director
Sold after exercise
7,712
$35.01
$270.00K
Maria C Freire
14 Feb 2025
Director
Sold after exercise
44,114
$34.94
$1.54M
George Poste
14 Feb 2025
Director
Sold after exercise
15,874
$34.74
$551.46K
Mary C Beckerle
14 Feb 2025
Director
Sold after exercise
3,856
$34.90
$134.57K
Mary C Beckerle
14 Feb 2025
Director
Sold after exercise
8,354
$34.87
$291.30K
Dana Aftab
5 Nov 2024
CSO/EVP Disc & Trans Research
Sold after exercise
96,986
$35.00
$3.39M
Jeffrey Hessekiel
26 Aug 2024
EVP, General Counsel & Sec
Sold after exercise
20,000
$25.79
$515.80K
Christopher J. Senner
9 Aug 2024
EVP and CFO
Sold after exercise
125,000
$27.19
$3.40M
Jeffrey Hessekiel
7 Aug 2024
EVP, General Counsel & Sec
Sold after exercise
80,000
$25.97
$2.08M
Dana Aftab
7 Aug 2024
CSO/EVP Disc & Trans Research
Sold after exercise
95,000
$25.00
$2.38M
George Poste
21 May 2024
Director
Sold after exercise
11,686
$20.96
$244.94K
Stelios Papadopoulos
20 May 2024
Director
Sold after exercise
11,437
$21.00
$240.18K
Jack L Wyszomierski
13 May 2024
Director
Sold after exercise
10,923
$21.37
$233.42K
Alan M Garber
21 Mar 2024
Director
Sold after exercise
19,205
$24.01
$461.11K
Patrick J. Haley
14 Dec 2023
EVP, Commercial
Sold after exercise
50,000
$23.35
$1.17M
Christopher J. Senner
4 Aug 2023
EVP and CFO
Sold after exercise
60,000
$20.68
$1.24M
Christopher J. Senner
3 Aug 2023
EVP and CFO
Sold after exercise
60,000
$20.51
$1.23M
Jeffrey Hessekiel
1 Aug 2023
EVP, General Counsel & Sec
Sold after exercise
55,710
$19.63
$1.09M
Jeffrey Hessekiel
5 Apr 2023
EVP, General Counsel & Sec
Sold after exercise
38,930
$20.01
$778.99K
Jack L Wyszomierski
10 Mar 2023
Director
Sold after exercise
15,300
$16.61
$254.13K
Jeffrey Hessekiel
1 Mar 2023
EVP, General Counsel & Sec
Sold after exercise
77,860
$17.13
$1.33M
Dana Aftab
28 Feb 2023
CSO/EVP Disc & Trans Research
Sold after exercise
82,490
$17.50
$1.44M
Dana Aftab
27 Feb 2023
CSO/EVP Disc & Trans Research
Sold after exercise
10
$17.50
$175.00
Alan M Garber
21 Feb 2023
Director
Sold after exercise
40,000
$17.49
$699.60K
Carl B Feldbaum
9 Feb 2023
Director
Sold after exercise
40,000
$17.78
$711.20K
Patrick J. Haley
6 Feb 2023
EVP, Commercial
Sold after exercise
25,000
$17.37
$434.25K
Peter Lamb
15 Dec 2022
EVP, Scientific Strategy & CSO
Sold after exercise
20,000
$15.88
$317.60K
George Poste
29 Nov 2022
Director
Sold after exercise
40,000
$16.68
$667.20K
Patrick J. Haley
12 Sep 2022
EVP, Commercial
Sold after exercise
40,000
$17.94
$717.60K
Lance Willsey
12 May 2022
Director
Sold after exercise
40,000
$19.65
$786.00K
Jack L Wyszomierski
4 Apr 2022
Director
Sold after exercise
6,696
$23.00
$154.01K
Patrick J. Haley
1 Apr 2022
EVP, Commercial
Sold after exercise
10,000
$23.00
$230.00K
Patrick J. Haley
31 Mar 2022
EVP, Commercial
Sold after exercise
10,000
$22.43
$224.30K
Alan M Garber
1 Mar 2022
Director
Sold after exercise
21,301
$21.00
$447.32K
Carl B Feldbaum
22 Feb 2022
Director
Sold after exercise
20,000
$19.49
$389.80K
Patrick J. Haley
3 Feb 2022
EVP, Commercial
Sold after exercise
60,000
$17.91
$1.07M
Peter Lamb
15 Dec 2021
EVP, Scientific Strategy & CSO
Sold after exercise
47,500
$17.44
$828.40K
Carl B Feldbaum
19 Nov 2021
Director
Sold after exercise
20,000
$17.62
$352.40K
Peter Lamb
15 Nov 2021
EVP, Scientific Strategy & CSO
Sold after exercise
47,500
$18.09
$859.28K
Peter Lamb
15 Oct 2021
EVP, Scientific Strategy & CSO
Sold after exercise
47,500
$21.92
$1.04M
Patrick J. Haley
16 Sep 2021
EVP, Commercial
Sold after exercise
25,000
$20.36
$509.00K
Peter Lamb
15 Sep 2021
EVP, Scientific Strategy & CSO
Sold after exercise
47,500
$20.46
$971.85K
Peter Lamb
16 Aug 2021
EVP, Scientific Strategy & CSO
Sold after exercise
55,000
$18.44
$1.01M
Peter Lamb
15 Jul 2021
EVP, Scientific Strategy & CSO
Sold after exercise
60,000
$17.47
$1.05M
Peter Lamb
17 Jun 2021
EVP, Scientific Strategy & CSO
Sold after exercise
60,000
$22.18
$1.33M
Vincent T Marchesi
14 May 2021
Director
Sold after exercise
40,000
$25.04
$1.00M
Gisela Schwab
13 May 2021
Pres, Prod Dev & Med Aff & CMO
Sold after exercise
100,000
$25.38
$2.54M
Stelios Papadopoulos
11 May 2021
Director
Sold after exercise
5,473
$25.01
$136.88K
Stelios Papadopoulos
11 May 2021
Director
Sold after exercise
5,075
$25.00
$126.88K
Stelios Papadopoulos
11 May 2021
Director
Sold after exercise
10,222
$24.95
$255.04K
Gisela Schwab
26 Apr 2021
Pres, Prod Dev & Med Aff & CMO
Sold after exercise
50,000
$25.00
$1.25M
Gisela Schwab
1 Apr 2021
Pres, Prod Dev & Med Aff & CMO
Sold after exercise
50,000
$23.00
$1.15M
Peter Lamb
1 Apr 2021
EVP, Scientific Strategy & CSO
Sold after exercise
60,000
$22.96
$1.38M
Jack L Wyszomierski
29 Mar 2021
Director
Sold after exercise
6,220
$22.64
$140.82K
Alan M Garber
15 Mar 2021
Director
Sold after exercise
40,000
$23.60
$944.00K
Peter Lamb
1 Mar 2021
EVP, Scientific Strategy & CSO
Sold after exercise
65,000
$22.11
$1.44M
Charles Cohen
24 Feb 2021
Director
Sold after exercise
40,000
$22.69
$907.60K
Lance Willsey
23 Feb 2021
Director
Sold after exercise
800
$22.34
$17.87K
Lance Willsey
23 Feb 2021
Director
Sold after exercise
39,200
$21.92
$859.26K
Gisela Schwab
18 Feb 2021
Pres, Prod Dev & Med Aff & CMO
Sold after exercise
50,000
$22.35
$1.12M
Gisela Schwab
17 Feb 2021
Pres, Prod Dev & Med Aff & CMO
Sold after exercise
50,000
$22.50
$1.13M
Carl B Feldbaum
16 Feb 2021
Director
Sold after exercise
20,000
$21.96
$439.20K
Peter Lamb
1 Feb 2021
EVP, Scientific Strategy & CSO
Sold after exercise
65,000
$22.08
$1.44M
Christopher J. Senner
12 Jan 2021
EVP and CFO
Sold after exercise
30,000
$25.00
$750.00K
Peter Lamb
4 Jan 2021
EVP, Scientific Strategy & CSO
Sold after exercise
65,000
$20.32
$1.32M
Peter Lamb
18 Dec 2020
EVP, Scientific Strategy & CSO
Sold after exercise
65,000
$20.01
$1.30M
Vincent T Marchesi
24 Nov 2020
Director
Sold after exercise
40,004
$18.50
$740.07K
Jack L Wyszomierski
10 Nov 2020
Director
Sold after exercise
34,000
$20.61
$700.74K
Jeffrey Hessekiel
21 Oct 2020
EVP and General Counsel
Sold after exercise
39,742
$21.95
$872.34K
Christopher J. Senner
8 Oct 2020
EVP and CFO
Sold after exercise
10,000
$25.00
$250.00K
Jeffrey Hessekiel
22 Sep 2020
EVP and General Counsel
Sold after exercise
10,258
$26.14
$268.14K
Patrick J. Haley
21 Sep 2020
EVP, Commercial
Sold after exercise
4,680
$26.09
$122.10K
Jeffrey Hessekiel
16 Sep 2020
EVP and General Counsel
Sold after exercise
20,000
$26.11
$522.20K
Christopher J. Senner
15 Sep 2020
EVP and CFO
Sold after exercise
20,000
$25.00
$500.00K
Peter Lamb
8 Jun 2020
EVP, Scientific Strategy & CSO
Sold after exercise
26,000
$22.56
$586.56K
Gisela Schwab
4 Jun 2020
Pres, Prod Dev & Med Aff & CMO
Sold after exercise
100,000
$22.96
$2.30M
Vincent T Marchesi
21 May 2020
Director
Sold after exercise
40,000
$24.64
$985.60K
Lance Willsey
18 May 2020
Director
Sold after exercise
30,000
$26.26
$787.80K
Lance Willsey
14 May 2020
Director
Sold after exercise
15,000
$25.26
$378.90K
Jeffrey Hessekiel
11 May 2020
EVP and General Counsel
Sold after exercise
38,006
$27.09
$1.03M
Vincent T Marchesi
11 May 2020
Director
Sold after exercise
30,000
$26.30
$789.00K
Patrick J. Haley
8 May 2020
EVP, Commercial
Sold after exercise
21,375
$25.87
$552.97K
Stelios Papadopoulos
8 May 2020
Director
Sold after exercise
45,000
$25.84
$1.16M
Christopher J. Senner
8 May 2020
EVP and CFO
Sold after exercise
78,583
$25.81
$2.03M
Jeffrey Hessekiel
8 May 2020
EVP and General Counsel
Sold after exercise
25,000
$26.04
$651.00K
Peter Lamb
7 May 2020
EVP, Scientific Strategy & CSO
Sold after exercise
50,000
$25.54
$1.28M
George Poste
7 May 2020
Director
Sold after exercise
30,000
$25.61
$768.30K
Carl B Feldbaum
7 May 2020
Director
Sold after exercise
31,546
$25.02
$789.28K
Christopher J. Senner
7 May 2020
EVP and CFO
Sold after exercise
21,417
$25.80
$552.56K
Jeffrey Hessekiel
7 May 2020
EVP and General Counsel
Sold after exercise
30,000
$25.61
$768.30K
Patrick J. Haley
23 Apr 2020
EVP, Commercial
Sold after exercise
5,000
$26.00
$130.00K
Gisela Schwab
23 Apr 2020
Pres, Prod Dev & Med Aff & CMO
Sold after exercise
100,000
$26.00
$2.60M
Patrick J. Haley
20 Apr 2020
EVP, Commercial
Sold after exercise
5,000
$24.00
$120.00K
Peter Lamb
6 Apr 2020
EVP, Scientific Strategy & CSO
Sold after exercise
50,000
$17.26
$863.00K
Jack L Wyszomierski
3 Apr 2020
Director
Sold after exercise
13,848
$16.57
$229.46K
Showing 250 of 499 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 706
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 8
Sales on a Rule 10b5-1 plan 26
Sales straight out of an exercise 283
Sales at will 131
Transactions with no price 0
Shares from compensation/vesting 41,557,913
Sales filed before the plan box existed 101
History held since 6 Oct 2006